Abstract 9207: Zofenopril and Ramipril Plus ASA in Post-myocardial Infarction Patients With Left Ventricular Systolic Dysfunction: A Post-hoc Analysis in Preserved or Impaired Left Ventricular Fraction at Entry

Abstract only Introduction: in the randomized, double-blind, parallel-group, multicenter, international SMILE-4 Study zofenopril 60 mg plus acetyl salicylic acid (ASA) was more effective than ramipril 10 mg plus ASA 100 mg in reducing 1-year occurrence of major cardiovascular (CV) events in patients...

Full description

Saved in:
Bibliographic Details
Published in:Circulation (New York, N.Y.) N.Y.), 2012-11, Vol.126 (suppl_21)
Main Authors: Borghi, Claudio, Ambrosioni, Ettore
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract only Introduction: in the randomized, double-blind, parallel-group, multicenter, international SMILE-4 Study zofenopril 60 mg plus acetyl salicylic acid (ASA) was more effective than ramipril 10 mg plus ASA 100 mg in reducing 1-year occurrence of major cardiovascular (CV) events in patients with acute myocardial infarction (AMI) complicated by left ventricular dysfunction (LVD). Objective: to compare zofenopril and ramipril efficacy in combination with ASA in a subgroup of patients of the SMILE-4 with preserved (>40%) or impaired (≤40%) left ventricular ejection fraction at the time of enrolment in the study. Methods: the SMILE-4 was a phase IIIb, randomized, double-blind, parallel-group, multicenter, European study comparing the safety and efficacy of zofenopril 60 mg/day and ramipril 10 mg/day plus ASA 100 mg/day, in patients with LVD (clinical signs of heart failure or a left ventricular ejection fraction or LVEF
ISSN:0009-7322
1524-4539
DOI:10.1161/circ.126.suppl_21.A9207